Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 3Phase 1/2 2Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 5fludarabine phosphate 4Azacitidine 4Gemtuzumab 3Decitabine 3Cytarabine 3Busulfan 3venetoclax 2Thiotepa 2Radiotherapy 2Methylprednisolone 2Melphalan 2Filgrastim 2Etoposide 2Antilymphocyte Serum 2vosaroxin 1vedolizumab 1tipifarnib 1midostaurin 1imetelstat 1cedazuridine 1baricitinib 1Whole-Body Irradiation 1Tretinoin 1Tacrolimus 1Stem Cell Transplantation 1Nuclear Receptor Subfamily 4, Group A, Member 2 1Nivolumab 1Methotrexate 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Myelodysplastic Syndromes × Hematopoietic Stem Cell Transplantation × Clear all
NCT04708054 2026-02-19

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

M.D. Anderson Cancer Center

Phase 2/3 Recruiting
324 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡